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The effect of high-dose steroid treatment used for the treatment of 
acute demyelinating diseases on endothelial and cardiac functions
Introduction
Multiple sclerosis (MS) and neuromyelitis optica (NMO) are 
inflammatory and demyelinating central nervous system (CNS) 
diseases characterized by acute exacerbations and remissions. 
They frequently affect young adults, and their disability rates are 
high (1). The brain, brain stem, cerebellum, spinal cord, and optic 
nerves can be involved either individually or combined, accor- 
ding to the subtypes of the disease. High-dose steroid treatment 
is frequently preferred in the acute exacerbation periods of the 
diseases regardless of the subtypes (2, 3). Recently, steroids 
have been successfully used not only in neurological diseases 
but also in acute exacerbations of renal diseases, musculoskele- 
tal system disorders, collagen vascular diseases, and dermato-
logical and hematological diseases (4, 5). Some early side effects 
are fluid retention, weight gain, high blood pressure, and mood 
changes (6). In long-term steroid use, cataracts, bone changes 
(osteoporosis or osteonecrosis), hypertension, lipid abnormali-
ties, diabetes and adrenal suppression, and diabetes suscepti-
bility can develop (7–9).
It is known that vascular function is deteriorated and that 
premature atherosclerosis is triggered after long-term steroid 
treatment for some chronic inflammatory diseases such as rheu-
matoid arthritis (10, 11). Furthermore, it has also been reported 
that sinus bradycardia, sinus tachycardia, and rhythm problems 
such as conduction system blocks or atrial fibrillation in the 
acute period can develop with high-dose steroid treatment (12, 
13). Accelerated atherosclerosis and cardiovascular mortality 
increase in Cushing’s disease patients exposed to long-term 
high-dose steroid treatment. However, it has been shown that 
short-term high-dose steroid treatment does not lead to the de-
terioration of endothelial function or increase in the carotid in-
tima–media thickness (cIMT) in healthy adults (14, 15). There are 
a limited number of studies in which the cardiovascular effects 
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of short-term high-dose steroid treatment have been examined. 
Therefore, in this study, we examined the effects of high-dose 
steroid treatment in acute demyelinating diseases on endothe-
lial and cardiac functions in the early and late periods. 
Methods
Study design
 This was a single-center, prospectively designed, observa-
tional study. This study was approved by Clinical Research and 
Ethical Committee (project no: KA15/351). 
Study group
In total, 35 consecutive patients (20 females and 15 males; mean 
age, 32.8±9.3 years) who did not receive any steroid treatment for 
MS according to the McDonald criteria (16) or for NMO according 
to the Wingerchuk criteria (17) were included in 6 months. Patients 
who had hypertension, diabetes mellitus, hyperlipidemia, chro- 
nic renal failure, cardiac insufficiency, collagen vascular dis-
ease, congenital heart disease, acquired valve disease, or atrial 
fibrillation were excluded. Furthermore, patients who smoked, 
who were obese [body mass index (BMI) >30], who were preg-
nant, who may be pregnant, who were using contraceptives, 
who were in the menstruation or luteal phase, who were not in 
the age group of 18 and 50 years, and who previously received 
steroids were excluded.
Study protocol
Patients were evaluated in three different periods: before 
high-dose steroid treatment (for 5 days, everyday; 1 g of methyl- 
prednisolone and 2 h of intravenous infusion in 5% dextrose so-
lution), 1 week after the end of treatment (early phase), and 3 
months after the end of treatment (late phase). In each evalu-
ation period, physical examinations were performed, and the 
blood pressures of patients were recorded. Furthermore, height 
and weight measurements were determined, and the BMIs of 
patients were calculated. Venous blood samples were collected 
after a 12-h starving period to measure the blood glucose, li- 
pid, creatinine, high-sensitivity C-reactive protein (hs-CRP), and 
whole blood levels. The brachial artery flow-mediated dilatation 
(FMD) test was performed to indirectly evaluate endothelial func-
tion. cIMT was assessed using Doppler ultrasound. The systolic 
and diastolic functions of the heart were echocardiographically 
evaluated. All these measurements were performed by the same 
cardiologist who was unaware of the measurement period and 
laboratory findings of patients. High-dose steroid treatment was 
given to patients after basal evaluation. This steroid treatment 
was not performed before the two following evaluations. 
Brachial artery FMD and cIMT measurement
Dilatation after transient ischemia of the brachial artery was 
ensured as it was previously defined (18). Measurements were 
performed using a 12-MHz linear vascular probe of a General 
Electric Vivid S6 (GE Healthcare, Chicago, USA) model echocar-
diography device. The brachial artery was longitudinally visu-
alized 3–5 cm above the antecubital fossa. The mean of three 
separate measurements of the basal systolic and diastolic 
diameters of the inner vessel were recorded. Then, a sphyg-
momanometer cuff was placed proximal to the section of the 
brachial artery and was inflated to 50 mm Hg higher than the 
systolic blood pressure. Systolic and diastolic diameters of the 
brachial artery were measured again 30 and 60 s after remo- 
ving the cuff at the end of the 5 min of ischemia. The difference 
between the baseline and hyperemic values were calculated as 
a percentage change.
Carotid Doppler ultrasound was performed as it was pre- 
viously described (19). Measurements were performed from the 
posterior wall and 10 mm proximal to the left and right carotid 
bifurcation. Both carotid measurements were repeated three 
times. The mean of the measurements was recorded as IMT. 
Echocardiographic examination
All patients were examined using 3V2c transthoracic probe 
of a Sequoia C256 (Siemens Healthcare GmbH, Germany) echo-
cardiography device. Measurements were performed from 
apical parasternal windows in the lateral decubitus position. 
Two-dimensional, M-mode, pulsed-wave (PW) Doppler and tis-
sue Doppler methods were used. Systolic and diastolic inter-
ventricular septum (IVS) thicknesses, posterior wall thickness, 
left ventricular end-systolic and end-diastolic diameters, aor-
tic systolic and diastolic diameters, and diastolic diameter of 
the left atrium were measured from the parasternal long axis 
using the M-mode. Ejection fraction (EF) was calculated u- 
sing the Teicholz method (20), and the left ventricular mass was 
calculated using the Devereux formula (21). The left ventricular 
mass index was calculated by dividing the left ventricular mass 
with the body surface area. The early diastolic flow velocity 
(E), late diastolic flow velocity (A), E/A ratio, E wave decelera-
tion time (EDT), and isovolumetric relaxation time (IVRT) were 
measured by placing the pulse Doppler sample volume on the 
tip of the mitral valve. We switched to the tissue Doppler mode 
to measure the regional myocardial velocity, and the gain was 
reduced to a minimum optimal level. The Doppler velocity range 
was set within the range of –30 and 30cm/s. The PW sample 
volume was placed at the level of the lateral wall mitral annulus 
and in the basal IVS in the apical four-chamber window. Early 
(Em) and late (Am) diastolic flow velocities and IVRT of both 
areas were calculated.
Statistical analysis
SPSS 15.0 (SPSS for Windows 15.0, Chicago, IL) was used 
for all statistical analyses. According to the power analysis, the 
minimum patient number was 15 (with 95% power). The variables 
were shown as mean±standard deviation. Pairwise comparisons 
of basal, 1-week, and 3-month findings were performed using a 
paired t-test. p<0.05 was accepted to be statistically significant. 
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Results
The general characteristics and laboratory findings of pa-
tients during the evaluation periods can be seen in Table 1. There 
was no difference between the heart rate; glucose, creatinine, 
hs-CRP, and serum lipid levels; and complete blood counts of pa-
tients. The basal body weight and mean BMI of patients were 
69.26±12.56 and 24.91±3.75, respectively. However, these values 
were 70.17±12.44 kg and 25.24±3.73, kg/m2 respectively, at 1 week 
after treatment and 70.60±12.63 and 25.39±3.73, respectively, at 3 
months after. The increase in the basal body weight and mean 
BMI at 1 week and 3 months after was significant (p<0.001) 
(Fig. 1a). Basal systolic and diastolic blood pressures were 
116.86±14.25 mm Hg and 72.43±8.94. The systolic and diastolic 
blood pressures at 1 week after treatment were 122.34±14.01 
and 78.66±10.27 mm Hg, respectively, and the corresponding 
pressures at 3 months after treatment were 124.57±12.74 and 
78.43±10.20. According to the systolic and diastolic blood pres-
sure measurements, there was a significant increase in the val-
ues at 1 week and 3 months after treatment compared to the 
basal values (for the systolic blood pressure: 1 versus 2, p=0.003 
and 1 versus 3, p<0.001, respectively; for diastolic blood pres-
sure, for both measurements, p<0.001) (Fig. 1b).
As a result of the comparison of the echocardiographic and 
Doppler findings at 1 week and 3 months after treatment with the 
basal values, we found that there was no significant decrease in 
the hyperemic brachial artery diameter at 1 week, whereas the 
reduction in the values at 3 months was significant (1 versus 2, 
p=0.576; 1 versus 3, p=0.003, respectively). On the other hand, 
there was a significant decrease in the FMD in both values at 1 
week and 3 months after treatment compared to basal values 
(1 versus 2, p=0.042; 1 versus 3, p=0.003, respectively) (Fig. 1c). 
There was no difference among the three measurements in 
terms of the cIMT (Fig. 1d), left ventricular mass, left ventricu-
lar mass index, EF, cardiac chamber size, and wall thickness. 
According to the conventional and tissue Doppler evaluations, 
there was a significant increase in the mitral A velocities values 
at 1 week and 3 months after treatment (1 versus 2, p=0.007; 1 
versus 3, p=0.003) (Fig. 2a), whereas there was a significant dec- 
rease in the mitral E/A ratio (Fig. 2b). There was a significant in-
crease in the mitral E deceleration time and IVRT at 3 months 
after treatment (Fig. 2c, d). Similarly, we observed an increase 
in lateral Am and septal Am wave velocities. There was a sig-
nificant prolongation particularly in the IVRT of both walls at 3 
months (Table 2).
Discussion
To our knowledge, this study is the first in which the effects 
of high-dose steroid treatment on endothelial and cardiac func-
tions were examined in demyelinating CNS diseases. In this 
study, we observed that high-dose steroid treatment negatively 
affected endothelial function and left ventricular diastolic func-
tion in the early and late periods. However, there was no diffe- 
rence in the cIMT. 
Steroids lead to an increase in angiotensin II type 1 receptors 
and α-1 receptors and a decrease in prostacyclin E2 synthesis 
in endothelial and vascular smooth muscle cells in experimental 
Table 1. Demographic characteristics and laboratory results
    After steroid treatment  P
  Basal (1) 1 week (2) 3 months (3) 1 versus 2 1 versus 3
Body weight, kg 69.26±12.56 70.17±12.44 70.60±12.63 <0.001 <0.001
Body mass index, kg/m2 24.91±3.75 25.24±3.73 25.39±3.73 <0.001 <0.001
Systolic BP, mm Hg 116.86±14.25 122.34±14.01 124.57±12.74 0.003 <0.001
Diastolic BP, mm Hg 72.43±8.94 78.66±10.27 78.43±10.20 <0.001 <0.001
Heart rate, beat/min 76.43±13.09 77.77±9.92 79.60±9.44 0.286 0.086
Glucose, mg/dL 89.31±11.09 91.63±10.31 90.06±10.48 0.131 0.648
Creatinine, mg/dL 0.74±0.13 0.78±0.16 0.75±0.16 0.085 0.526
C-reactive protein, mg/L 3.11±3.06 3.76±2.91 3.21±2.21 0.233 0.820
Triglyceride, mg/dL 128.91±55.70 135.86±72.04 135.91±56.20 0.160 0.111
HDL-cholesterol, mg/dL 50.34±12.64 49.46±12.44 50.23±12.32 0.212 0.886
LDL-cholesterol, mg/dL 98.77±25.60 98.43±29.00 102.43±32.85 0.850 0.147
Hemoglobin, g/dL 13.96±1.63 13.80±1.49 13.96±1.42 0.196 0.134
Hematocrit, % 42.17±4.49 41.77±4.49 41.91±4.40 0.689 0.503
Leukocyte, 1000/µL 7.48±2.23 7.74±2.31 7.34±1.70 0.503 0.629
Lymphocyte, % 28.54±10.58 27.84±9.99 28.95±9.09 0.720 0.867
Neutrophil, % 62.18±12.88 61.58±12.13 60.15±10.98 0.816 0.471
BP - blood pressure; HDL - high-density lipoprotein; LDL - low-density lipoprotein. A paired t-test was used for statistical analyses
Çaldır et al.
High-dose steroid therapy Anatol J Cardiol 2017; 17: 392-7394
models. Consequently, the blood pressure increases (22). It has 
also been observed that steroids lead to the in vitro production 
of superoxide radicals in endothelial cells in addition to their 
well-known metabolic effects (23). Further, in our study, signifi-
cant early and late weight gains and increased BMIs and blood 
pressures were observed after high-dose steroid treatment. All 
these mechanisms may be related to the prominent deteriora-
tion of brachial artery FMD, which is an important indicator of 
endothelial dysfunction detected after high-dose steroid treat-
ment. Nevertheless, an improvement in FMD has been reported 
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Figure 1. Body mass index (a), systolic blood pressure (BP) (b), flow-mediated dilatation (c), carotid intima–media thickness (cIMT) (d), and basal, 
first week, and third month values
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Figure 2. Mitral A velocity (a), mitral E/A ratio (b), mitral E deceleration time (c), mitral isovolumetric relaxation time (d), and basal, first week, and 
third month values
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with steroid treatment in patients with inflammatory vascular 
diseases as giant cell arteritis (24).
Vascular endothelium homeostasis changes are observed 
in the development of atherosclerosis, which is a complex and 
multi-factorial process. It is accepted that the FMD of the deterio-
rated brachial artery is an indicator of endothelial dysfunction. It is 
also an early sign of atherosclerosis because they have common 
pathophysiological processes (25, 26). In our study, we examined 
the cIMT to evaluate atherosclerosis development. However, we 
did not detect any changes in the early or late periods. We believe 
that this was because our study was performed in a relatively short 
time period. There should be long-term studies where we can eval-
uate these patients in terms of atherosclerosis development.
It has been shown that there was deterioration in diastolic 
function and an increase in the left ventricular mass depending 
on increased blood steroid levels in Cushing's disease patients. 
Furthermore, it was related to increased cardiovascular morta- 
lity (27). In this study, there were findings in line with diastolic 
dysfunction in mitral flow and tissue Doppler velocities. Diastolic 
dysfunction is accepted as the earliest finding in heart failure, 
and the myocardial response depends on the coronary artery 
disease. Heart failure with preserved EF and deteriorated dias- 
tolic function is similar to heart failure with low EF. A diagnosis 
of diastolic dysfunction is very important because it is difficult to 
diagnose and is very easy to be ignored (28). In line with these 
findings, it can be stated that undesirable major cardiovascular 
events can develop in patients after high-dose steroid treatment. 
Study limitations
The most important limitation of this study is the low number 
of patients. It was difficult to find a greater number of patients 
who complied with the inclusion and exclusion criteria. 
Patients were evaluated for a period of 3 months. However, 
more time may be required to examine the cIMT and left ventri- 
cular mass increase. Additional radiological examinations such 
as cardiac magnetic resonance imaging could provide more ac-
curate results. Furthermore, studies with long follow-up periods 
of pulse steroid treatment might show no adverse effect on ED 
and diastolic dysfunction due to spontaneous remission. 
Table 2. Echocardiographic and Doppler measurement results
    After steroid treatment  P
  Basal (1) 1 week (2) 3 months (3) 1 versus 2 1 versus 3
Brachial artery diameter (basal), mm 3.04±0.56 3.06±0.51 3.06±0.47 0.576 0.475
Brachial artery diameter (hyperemia), mm 3.67±0.54 3.54±0.49 3.47±0.51 0.053 0.003
FMD change, % 20.58±9.20 16.76±10.49 13.82±10.63 0.042 0.003
cIMT, mm 0.55±0.19 0.55±0.12 0.56±0.12 0.865 0.186
Left ventricular mass, g 212.66±73.57 213.89±64.28 220.26±67.81 0.757 0.089
Left ventricular mass index, g/m2 125.63±41.48 127.40±35.75 130.03±40.04 0.549 0.208
Ejection fraction,% 68.57±6.12 69.40±5.20 68.94±4.83 0.192 0.563
Left atrial diameter, mm 32.7±4.4 33.0±4.0 33.1±3.9 0.138 0.112
Interventricular septum thickness, mm 10.1±1.30 10.2±1.2 10.0±2.5 0.103 0.993
Posterior wall thickness, mm 9.9±1.6 10.1±1.3 10.1±2.1 0.314 0.792
LV (systole), mm 28.6±3.9 28.4±3.1 28.9±3.4 0.592 0.295
LV (diastole), mm 44.7±5.27 44.7±4.8 44.8±4.8 0.991 0.594
Mitral E, cm/s 91.20±25.81 90.54±25.80 91.94±26.18 0.654 0.675
Mitral A, cm/s 56.86±12.49 64.51±18.42 67.20±21.30 0.007 0.003
Mitral E/A 1.67±0.56 1.47±0.48 1.43±0.38 0.013 0.006
Mitral EDT, ms 168.09±37.57 175.40±36.05 188.83±41.36 0.104 <0.001
IVRT, ms 96.83±19.25 100.89±24.85 107.34±25.77 0.244 0.005
Lateral Em, cm/s 21.17±5.49 20.23±5.99 19.57±6.02 0.100 0.052
Lateral Am, cm/s 14.77±5.56 16.28±5.38 17.66±5.68 0.045 0.007
Lateral IVRT, ms 84.94±15.16 85.37±14.07 90.20±12.84 0.851 0.021
Septal Em, cm/s 18.29±4.919 18.15±4.34 17.86±4.45 0.825 0.505
Septal Am, cm/s 13.43±4.10 15.80±4.96 14.91±3.70 <0.001 0.003
Septal IVRT, ms 89.26±15.71 90.34±17.06 93.91±17.87 0.605 0.037
EDT - E wave deceleration time; FMD - flow-mediated dilatation; cIMT - carotid intima–media thickness; IVRT - isovolumetric relaxation time; LV - left ventricle. A paired t-test was 
used for statistical analyses
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Conclusion
In our study, we detected significant weight gain, increase 
in blood pressure, left ventricular diastolic dysfunction, and en-
dothelial dysfunction as a result of pulse steroid treatment in 
patients who did not have cardiovascular risk factors. However, 
we did not detect an increase in the left ventricular mass and 
an increase in the cIMT that is accepted as an early indicator of 
atherosclerosis. 
Consequently, patients who required pulse steroid adminis-
tration should be closely monitored in terms of cardiovascular 
mortality and morbidity, and further investigations are required.
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